Sudan's renewed medtech prospects on hold:
This article was originally published in Clinica
Executive Summary
Ongoing instability in the Darfur region of Sudan has put paid to any immediate prospect of resuming much-needed healthcare improvements. The situation has essentially obviated the calls made in July to meet shortfalls in medical supplies, diagnostic services and hospital infrastructures (see Clinica No 1117, p 13). International efforts were expected to resume last week, when the government signed a series of security and humanitarian access agreements, in response to widespread condemnation of the severe social instability in the region. The UN Security Council is due to meet on November 18, in Nairobi, Kenya, to discuss the situation and consider sanctions.
You may also be interested in...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.